The min mouse on FVB background: Susceptibility to spontaneous and carcinogen-induced intestinal tumourigenesis

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 785-788

  Svendsen, Camilla ^a   Alexander, Jan ^a   Knutsen, Helle K ^a   Husøy, Trine ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

2 amino 1 methyl 6 phenylimidazo 4,5 b pyridine; Apc; C57B1 6J; FVB; Intestinal carcinogenesis; Min mice

Indexed keywords

2 AMINO 1 METHYL 6 PHENYLIMIDAZO[4,5 B]PYRIDINE;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CANCER MODEL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMALL INTESTINE CANCER;

ABERRANT CRYPT FOCI; ANIMALS; BREEDING; CARCINOGENS; DISEASE SUSCEPTIBILITY; INTESTINAL NEOPLASMS; LITTER SIZE; LONGEVITY; MICE; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; PRECANCEROUS CONDITIONS;

EID: 79956065172     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Moser AR, Pitot HC and Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324, 1990.
2. Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR and Dove WF: ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer 31A: 1061-1064, 1995.
3. Moser AR, Dove WF, Roth KA and Gordon JI: The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. J Cell Biol 116: 1517-1526, 1992.
4. Steffensen IL and Alexander J: Impact of genetic background on spontaneous or 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP)-induced intestinal tumorigenesis in Min/+ mice. Cancer Lett 240: 289-296, 2006.
5. Ritland SR and Gendler SJ: Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 20: 51-58, 1999. (Pubitemid 29033844)
6. Moser AR, Hegge LF and Cardiff RD: Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc(min)/+ mice. Cancer Res 61: 3480-3485, 2001. (Pubitemid 32695044)
7. Øistørn HBA: The Effect of Acrylamide and Glycidamide on Intestinal Carcinogenesis in Mice. 2009. Faculty of Mathematics and Natural Sciences, University of Oslo.
8. McCart AE, Vickaryous NK and Silver A: Apc mice: models, modifiers and mutants. Pathol Res Pract 204: 479-490, 2008.
9. MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD and Buchberg AM: The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell 81: 957-966, 1995.
10. Olstorn HB, Paulsen JE and Alexander J: Effects of perinatal exposure to acrylamide and glycidamide on intestinal tumorigenesis in Min/+ mice and their wild-type litter mates. Anticancer Res 27: 3855-3864, 2007.
11. Andreassen A, Mollersen L, Vikse R, Steffensen IL, Mikalsen A, Paulsen JE and Alexander J: One dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) or 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) induces tumours in Min/+ mice by truncation mutations or LOH in the Apc gene. Mutat Res 577: 157-166, 2002. (Pubitemid 34597015)
12. Taketo M, Schroeder AC, Mobraaten LE, Gunning KB, Hanten G, Fox RR, Roderick TH, Stewart CL, Lilly F, Hansen CT et al: FVB/N: an inbred mouse strain preferable for transgenic analyses. Proc Natl Acad Sci USA 88: 2065-2069, 1991. (Pubitemid 21916354)
13. Steffensen IL, Paulsen JE, Eide TJ and Alexander J: 2-Amino-1-methyl-6- phenylimidazo[4,5-b]pyridine increases the numbers of tumors, cystic crypts and aberrant crypt foci in multiple intestinal neoplasia mice. Carcinogenesis 18: 1049-1054, 1997.
14. Weber EM, Olsson AS and Algers B: High mortality rates among newborn laboratory mice - is it natural and which are the causes? Acta Vet Scand 49(Suppl 1): S8, 2007.
15. + Mom1S mice. Proc Natl Acad Sci USA 102: 2868-2873, 2005.